DUSA Pharmaceuticals to Present at Roth Capital Partners 20th Annual Growth Stock Conference
For release at 8:00 a.m.Contact:
Chad Rubin, Investor Relations Contact, The Trout Group LLC - 646.378.2947
DUSA Pharmaceuticals to Present at
Roth Capital Partners 20th Annual Growth Stock Conference
WILMINGTON, Mass. - February 13, 2008 - DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan® photodynamic therapy (PDT) and other products targeting patients with common skin conditions, today announced that Bob Doman, President & Chief Executive Officer will present at the Roth Capital Partners 20th Annual Growth Stock Conference. The conference is being held at The Ritz Carlton Laguna Niguel, Dana Point, California February 18-22, 2008. Mr. Doman is scheduled to present at 1:00 p.m. Pacific Time (4:00 p.m. Eastern Time) on Wednesday, February 20.
Investors may listen to the live webcast and view a copy of the slide presentation online via the "Investors" section of the Company's web site at www.dusapharma.com. The recorded webcast will be accessible online for at least 30 days. Attendance at the Roth Capital Partners Conference is by invitation only.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc. is an integrated dermatology specialty pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy (PDT) technology platform, and complementary dermatology products. Levulan® PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses of the face and scalp, and is being developed for the treatment of acne. DUSA's other dermatology products include ClindaReachTM and Nicomide®. DUSA is also supporting development of certain internal indications of Levulan® PDT. DUSA is based in Wilmington, Mass. Please visit our Web site at www.dusapharma.com.